Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$20.01 USD
-0.17 (-0.84%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $20.03 +0.02 (0.10%) 5:22 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
FLGT 20.01 -0.17(-0.84%)
Will FLGT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FLGT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FLGT
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
American Well Corporation (AMWL) Reports Q1 Loss, Misses Revenue Estimates
FLGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Privia Health (PRVA) Misses Q4 Earnings Estimates
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
Other News for FLGT
Fulgent Genetics: Growth Is Returning
What's Driving Twist Bioscience Corp's Surprising 15% Stock Rally?
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics